Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn how effective the drug pemetrexed
(ALIMTA®) is in treating advanced NSCLC in patients with poor performance status (PS)
(inability to perform every day activities without difficulty).
Objectives:
Primary Objectives:
- PS = 2 cohort: Response
- PS = 3 cohort: Descriptive
Secondary Objectives:
- Tolerability of single agent pemetrexed (Alimta®) in PS = 3 NSCLC patients
- Improved symptoms (both cohorts)
- Molecular Correlative studies (both cohorts)
- Overall survival
- Time to progression